The 3 most important recent advances in nephrology

Jürgen Floege

Dr Jürgen Floege is a professor of medicine, director of the Division of Nephrology and Clinical Immunology at the University Hospital RWTH Aachen, Germany, and Distinguished Fellow of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA).

If you were to name the 3 most important recent advances relevant for everyday practice in nephrology, what would they be?

Jürgen Floege, MD, PhD: The 3 most important recent advances in nephrology… Number 1 for me, undoubtedly, this year, is the publication of 3 major guideline updates by the KDIGO group. KDIGO—Kidney Diseases: Improving Global Outcomes—is a nonprofit organization that provides worldwide guidelines. Guideline number 1, which was just updated, is [on] diabetes and the kidney with, of course, a much stronger emphasis on sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Guideline number 2, which was just updated and published, is [on] blood pressure in chronic kidney disease, giving you targets that you should aim for. In September we will publish a huge guideline on all glomerular diseases—so, glomerulonephritis, vasculitis, and lupus nephritis [at the time of publication of the interview, the guidelines have already been released and can be accessed here]. And this will set the worldwide standard on how to treat these diseases.

Advance number 2, undoubtedly, for nephrology, is the introduction of SGLT-2 inhibitors and the realization that SGLT-2 inhibitors are probably not just antidiabetic drugs but may have the potential to become a “one for everyone with chronic kidney disease,” like angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We now have very good data emerging: the DAPA-CKD [trial], and the EMPA-KIDNEY study will come out next year, but the data show that SGLT-2 inhibitors also work in nondiabetic kidney disease, because they seem to be very nephroprotective and you can add them on top of a renin-angiotensin system (RAS) blocker with essentially very few adverse events.

And number 3 in terms of advances, at least for me, is this whole development of complement inhibition. We are already using eculizumab—I talked about this in my lecture—we’ve recently added ravulizumab, a long-acting form of an [anti-]C5 antibody, to the armamentarium, but the latest was just a few days ago: the publication of the ADVOCATE trial, where we now use a C5a receptor antagonist, avacopan, in antineutrophil cytoplasmic antibody (ANCA)[–associated] vasculitis. And I think—and I’m absolutely certain—that in the next years, we will see many more situations where the complement can be targeted very specifically. And we will have a new therapy for kidney diseases, immunologic diseases that may be much, much more targeted than the high-dose corticosteroids we used to give. So, for me, these are the key 3 developments this year.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.